EMA Refused: Heparesc (human heterologous liver cells) — Cytonet GmbH KG

View source ↗

Summary

The EMA refused the marketing authorization for Heparesc (human heterologous liver cells) by Cytonet GmbH KG for urea cycle disorders, Inborn, in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urea Cycle Disorder

Drugs mentioned

• Heparesc (human heterologous liver cells)

Snippet

Status: Refused. Therapeutic area: Urea Cycle Disorders, Inborn. MAH: Cytonet GmbH KG. Decision date: 22/10/2015. Orphan medicine